CCNA1 and breast cancer: Our finding on that cyclin A1 is involved in the modulation of both ER-α and VEGF pathways may provide novel insights into treatment of breast cancer and may be helpful for designing novel drugs to selectively target invasive breast cancer cells in clinical settings.